ArticleHuman vaccines & immunotherapeutics2025
Reclaiming momentum: The Essential Programme on Immunization in the journey to 2030 and beyond.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation.Infection and drug resistance · 2026Review
- Strategic positioning of immunization at the heart of Africa's health and development agenda.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fifty-one years after the launch of the Expanded Programme on Immunization - now rebranded as the Essential Programme on Immunization - routine vaccination remains the most transformative public health intervention, preventing more than 154 million deaths globally. Yet despite this historic gain, the world is at a critical juncture. Since 2020, more than 20 million children are left under-vaccinated each year, leading to outbreaks of vaccine-preventable diseases. In our view, the greatest risk is the normalization of stagnation, where failure to attain optimal coverage is passively accepted as the new normal. This moment demands more than recovery; it requires renewed momentum, bold accountability, and strategies tailored to local realities. We argue that three accelerators are essential: embedding immunization within resilient primary health care systems, addressing vaccine hesitancy through trust-building and continuous engagement, and securing sustainable financing linked to equity goals. Implementation science must inform these actions, ensuring lessons are documented and adapted across contexts. The next 5 y, leading to 2030, will decide whether immunization delivers on its promise of protection for all or retreats into entrenched inequities. We contend that only political will, solidarity, and systematic learning can safeguard vaccines as a global public good for future generations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.